Wednesday, June 10, 2026

Patent intelligence · US

US 8658648

Modified chloroquines with single ring moiety or fused ring moiety

granted A61KA61K31/047A61PA61P31/00
Status granted
Linked drugs 1
Pipeline programs 6
Years to expiry 8
Applicant portfolio 201
Patent details — US 8658648
Jurisdiction
US
Status
granted
Grant date
Feb 25, 2014
Expiration
Feb 20, 2034
Applicant
DesignMedix, Inc.
Claims
6
CPC classes
A61K, A61K31/047, A61P, A61P31/00
View on Google Patents ↗

Quick answer

US 8658648 (Modified chloroquines with single ring moiety or fused ring moiety) is held by DesignMedix, Inc.. Status: granted. Granted Feb 25, 2014. Expires Feb 20, 2034 (8 years remaining) — relevant for patent-cliff and LOE planning.

Key facts

Applicant
DesignMedix, Inc.
Grant date
Expiration
Claims
6
CPC classes
A61K, A61K31/047, A61P, A61P31/00, A61P33/02

More from DesignMedix, Inc.

Related pharmaceutical patents in our USPTO index.

  1. US 12378245

    Crystalline forms of an RSK inhibitor

    PHOENIX MOLECULAR DESIGNS · Expires Jul 31, 2045

    granted
  2. US 12297243

    Methods and compositions for reducing the immunogenicity of chimeric notch receptors

    Cell Design Labs, Inc. · Expires May 8, 2045

    granted
  3. US 12291058

    Dispersions for additive manufacturing comprising discrete carbon nanotubes

    MOLECULAR REBAR DESIGN, LLC · Expires May 1, 2045

    granted
  4. US 12268695

    Betulin-containing birch bark extracts and their formulation

    Amryt Pharmaceuticals Designated Activity Company · Expires Apr 3, 2045

    granted
  5. US 12247004

    2-amino-N-(amino-oxo-aryl-lambda6-sulfanylidene)acetamide compounds and their therapeutic use

    Oxford Drug Design Limited · Expires Mar 6, 2045

    granted
  6. US 12065498

    Methods of making bispecific anti-CD307E and anti-BCMA chimeric antigen receptors and uses of the same

    Cell Design Labs, Inc. · Expires Aug 15, 2044

    granted
  7. US 12005194

    Configurable oxygen concentrator and related method

    SEPARATION DESIGN GROUP LLC · Expires Jun 6, 2044

    granted
  8. US 11998571

    Pharmaceutical composition comprising stem cell-conditioned medium and exosome isolated therefrom as active ingredient for prevention or treatment of ocular disease

    DESIGNED CELLS CO., LTD. · Expires May 30, 2044

    granted

Frequently asked questions

What is US patent 8658648?

US 8658648 (Modified chloroquines with single ring moiety or fused ring moiety) is held by DesignMedix, Inc.. Status: granted. Granted Feb 25, 2014. Expires Feb 20, 2034 (8 years remaining) — relevant for patent-cliff and LOE planning.

Who owns US 8658648?

DesignMedix, Inc. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 201 pharmaceutical patents for this assignee.

When does US 8658648 expire?

Our index shows an expiration date of Feb 20, 2034 (8 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.